Tofacitinib, a JAK1/3 Inhibitor As Treatment for Linear IgA Bullous Dermatosis: A Case Report
2023; Lippincott Williams & Wilkins; Volume: 34; Issue: 2 Linguagem: Inglês
10.1089/derm.2022.29007.bfa
ISSN2162-5220
Autores Tópico(s)Eosinophilic Disorders and Syndromes
ResumoDermatitis®Vol. 34, No. 2 LettersTofacitinib, a JAK1/3 Inhibitor As Treatment for Linear IgA Bullous Dermatosis: A Case ReportBirao Fan and Mingyue WangBirao FanDepartment of Dermatology, Peking University First Hospital, Beijing, ChinaNational Clinical Research Center for Skin and Immune Diseases, Beijing, ChinaBeijing Key Laboratory of Molecular Diagnosis on Dermatoses, Beijing, ChinaSearch for more papers by this author and Mingyue WangE-mail Address: [email protected]Department of Dermatology, Peking University First Hospital, Xishiku Street, Xicheng District, Beijing 100034, ChinaNational Clinical Research Center for Skin and Immune Diseases, Beijing, ChinaBeijing Key Laboratory of Molecular Diagnosis on Dermatoses, Beijing, ChinaSearch for more papers by this authorPublished Online:16 Mar 2023https://doi.org/10.1089/derm.2022.29007.bfaAboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookXLinked InRedditEmail View articleFiguresReferencesRelatedDetails Volume 34Issue 2Apr 2023 Information© 2023 American Contact Dermatitis Society. All Rights Reserved.To cite this article:Birao Fan and Mingyue Wang.Tofacitinib, a JAK1/3 Inhibitor As Treatment for Linear IgA Bullous Dermatosis: A Case Report.Dermatitis®.Apr 2023.160-161.http://doi.org/10.1089/derm.2022.29007.bfaPublished in Volume: 34 Issue 2: March 16, 2023Online Ahead of Print:January 19, 2023 PDF download
Referência(s)